Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEU-PED: V114 vs Prevnar 13 in Healthy Infants
NCT03893448Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- May 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 4
01
Overview
A Phase 3 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Jun 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03893448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893448.